Mebeverine

DB12554ApprovedInvestigationalWithdrawnSmall molecule

Mebeverine is an antispasmodic used for the symptomatic treatment of stomach pain and spasms associated with irritable bowel syndrome and other gastrointestinal illnesses.

Formula / weight: C₂₅H₃₅NO₅ · 429.557 g/mol (avg)
Code names: BRN 2783282

Resolves to

Compound

UNII7F80CC3NNVCAS3625-06-7ChEMBLCHEMBL282121ChEBI91514PubChem4031

Clinical / RWD

RxNorm29410ATCA03AA04

Structure

InChIKeyVYVKHNNGDFVQGA-UHFFFAOYSA-NSMILESCCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1

Targets

P08912CHRM5

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

606Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

5Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

97Marketed productsAcross 9 countries and 28 labellers

1ATC codeIncluding every combination product, plus 13 drug categories

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Mebeverine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account